Typically, however, semaglutide GLP-1 is meant for obese patients and the general rule of thumb is that its intended for patients with a body mass index (BMI) of 27kg/m2 or higher and/or another condition related to being overweight
Some telehealth outfits have signaled their intention to continue offering their products.Now that the FDA has determined the drug shortage for semaglutide has been resolved, we will continue to offer access to personalized treatments as allowed by law to meet patient needs, Andrew Dudum, founder and CEO of Hims & Hers Health, wrote on X, adding that the company is closely monitoring potential future shortages
The FDA has also issued an alert on dosing errors associated with compounded semaglutide injectable products, which have led to adverse events and hospitalisations in some cases
Blood sugar implications For people using tirzepatide for type 2 diabetes management (Mounjaro), potency loss has more immediate clinical significance
Repeatedly injecting into the same spot can lead to complications that may affect treatment efficacy and patient comfort
